ClinicalTrials.gg
Active, not recruitingNCT05349214NEPTUNUS-2Updated Jun 17, 2026

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

A Phase 3 interventional study of VAY736 and Placebo in Sjogren Syndrome, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 146 sites in 26 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
506
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.

Enrollment
4th of 14
506 · median 240
Started
2022
with 2 others
Phase 3
4 of 15
1 open now
Registered
11th of 15
by date

Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 11th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Sjogren's Syndrome by Novartis, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)

Read the detailed description

Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjogren's syndrome. The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of ianalumab (VAY736) administered subcutaneously (s.c.) monthly or every 3 months compared to placebo in patients with active Sjogren's syndrome.

03

Conditions studied

  • Sjogren Syndrome

Browse trials for

Keywords

  • Sjogren's syndrome, B-cell depleting, BAFF-R, VAY736, ianalumab, NEPTUNUS
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study
  • Women and men ≥ 18 years of age
  • Classification of Sjögren's syndrome according to the ACR/EULAR 2016 criteria
  • Time since diagnosis of Sjögren's of ≤ 7.5 years at screening
  • Positive anti-Ro/SSA antibody at screening

    • Patients negative for anti-Ro/SSA antibody are eligible, if they have a positive salivary gland confirmed by central expert review
    • Enrollment of anti-Ro/SSA-negative patients will be limited up to ≤10% of the study population
  • Screening ESSDAI score of ≥ 5 within the following 8 domains: constitutional, lymphadenopathy, glandular, articular, cutaneous, renal, hematological and biologic.
  • Stimulated whole salivary flow (sSF) rate of ≥ 0.05 mL/min at screening
  • Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study
  • Patients taking hydroxychloroquine (≤ 400 mg/day), methotrexate (≤ 25 mg/week) or azathioprine (≤ 150 mg/day) alone or in combination, are allowed to continue their medication, and must have been on a stable dose for at least 30 days prior to randomization.
  • Patients taking systemic have to be on a stable dose of ≤ 10 mg/day predniso(lo)ne or equivalent for at least 30 days before randomization.
  • Patients taking

    • disease-modifying antirheumatic drugs (DMARDs) other than specifically allowed in inclusion criterion #9 or
    • the following Traditional Chinese Medicines: Total glucoside of peony (TGP) or Tripterium glycosides (TG) must discontinue these medications at least 30 days prior to randomization, except for leflunomide, which has to be discontinued for 8 weeks prior to randomization unless a cholestyramine wash-out has been performed.

Exclusion criteria

Exclusion Criteria:

  • Presence of another rheumatic disease that is active and constitutes the principal illness
  • Use of other drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer3. Prior treatment with ianalumab
  • Prior use of a B-cell depleting therapy other than ianalumab within 36 weeks prior to randomization or as long as B-cell count is less than the lower limit of normal or baseline value prior to receipt of previous B cell-depleting therapy (whichever is lower)
  • Prior treatment with any of the following:

    1. Within 24 weeks prior to randomization: iscalimab (anti CD-40 mAb), belimumab , abatacept, anti-tumor necrosis factor alpha biologic agents, immunoglobulins plasmapheresis;
    2. Within 12 weeks prior to randomization: i.v. or oral cyclophosphamide, mycophenolate mofetil, i.v. or oral cyclosporine A or any other (e.g., JAK inhibitors or other kinase inhibitors) unless explicitly allowed by protocol
  • Use of (predniso(lo)ne or equivalent corticosteroid) at dose >10 mg/day
  • Any one of the following laboratory values at screening:

    • levels \< 8.0 g/dL
    • White blood cells (WBC) count \< 2.0 x 10E3/µL
    • count \< 80 x 10E3/µL
    • (ANC) \< 0.8 x 10E3/µL
  • Active viral, bacterial or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent infection or of recurrent bacterial infections with encapsulated organisms
  • History of to any of the study drugs or its or to drugs of similar chemical classes (e.g., mAb of IgG1 class) or to any of the constituents of the study drug formulation (sucrose, L-histidine hydrochloride/ L-histidine, polysorbate 20)
  • History of major organ, hematopoietic stem cell or bone marrow transplant
  • Required regular use of medications known to cause dry mouth/eyes as a regular and major side effect, and which have not been on a stable dose for at least 30 days prior to Screening, or any anticipated change in the treatment regimen during the course of the study.
  • Use of topical ocular prescription medications (excluding artificial tears, gels, lubricants) that have not been on a stable dose for at least 90 days prior to randomization, or any anticipated change in the treatment regimen during the course of the study
  • Receipt of live/attenuated vaccine within a 4-week period prior to randomization
  • History of primary or secondary immunodeficiency, including a positive (HIV) test result
  • History of of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer or Sjögren's related lymphoma), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  • History of sarcoidosis
  • Any surgical, medical (e.g., uncontrolled hypertension, heart failure or diabetes mellitus), psychiatric or additional physical condition that the Investigator feels may jeopardize the patient in case of participation in this study
  • Chronic infection with (HBV) or (HCV) virus. Positive serology for hepatitis B surface antigen (HBsAg) excludes the subject.

    • HBsAg negative subjects who are hepatitis B core antibody (HBcAb) positive are also excluded unless all of the following criteria are met:

      1. HBV DNA is negative
      2. hepatitis B monitoring is implemented - in these subjects, monthly testing of HBsAg and HBV DNA must be performed while on study treatment and at least every 12 weeks after end of treatment for the entire duration of safety follow-up.
      3. Antiviral prophylaxis must be implemented before the first administration of the study treatment, and continued up to 12 months after end of study treatment. If antiviral therapy cannot be given or if the patient is not willing to comply with the antiviral treatment requirement, the patient is not eligible for the study.
    • Hepatitis C: patients with positive hepatitis C antibody and HCV-RNA at screening are excluded. Chronic hepatitis C patients who have completed HCV anti-viral treatment must be HCV-RNA negative at least 12 weeks after treatment before randomization to be eligible. Cases of spontaneous HCV clearance should be discussed with sponsor before enrollment.
  • Evidence of active tuberculosis (TB) infection is exclusionary. Patient with previously treated TB and previously treated or newly diagnosed latent TB may be eligible.
  • Pregnant or nursing (lactating) women,
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while on study treatment and for 6 months after stopping of investigational medication.
  • Patients with a known history of non-compliance to medication, or who were unable or unwilling to complete PRO questionnaires, or who are unable or unwilling to use the device for collection of PROs.
  • United States (and other countries, if locally required): Sexually active males, unless they agree to use barrier protection during intercourse with a woman of childbearing potential, while taking study treatment. As condom use alone has a reported failure rate exceeding 1% per year, it is recommended that female partners of male study participants use a second method of birth control.

Although ianalumab is not teratogenic and/or genotoxic, and not transferred to semen, male contraception is required, as requested by FDA.

Globally, for all sexually active males, contraception should be used in accordance with locally approved prescribing information of concomitant medications administered.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
506 participants (actual)

Study arms

  • Experimental
    Arm A

    ianalumab exposure level 1

    Biological: VAY736

  • Experimental
    Arm B

    ianalumab exposure level 2

    Biological: VAY736

  • Placebo comparator
    Arm C

    placebo

    Other: Placebo

Interventions

  • BiologicalVAY736

    ianalumab s.c.

  • OtherPlacebo

    placebo s.c.

06

What researchers measure

Primary outcomes

  1. Plan A and B - Change from baseline in ESSDAI score at Week 48

    * Plan A - United States of America and US reference countries * Plan B - EU, China, other non-US Regions and EU reference countries Dose response measured by change multi-dimensional disease activity as assessed by the physician. Score range is 0-123. Higher scores on the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states A negative change from baseline indicates improvement in disease status.

    Time frame: 48 weeks

Secondary outcomes

  1. Change from baseline in SSSD score at Week 48

    Efficacy (Plan A and B) The Sjogrens Syndrome Symptom Diary (SSSD) is questionnaire consists of five (six for females) questions about symptoms of Sjögren's syndrome, each question given a score of 0-10 (0=no symptoms, 10=worst possible symptoms) where patient choose the one response that best describes how severe the symptom was at its worst in the PAST 24 HOURS. It includes six symptom items (eye dryness, mouth dryness, skin dryness, physical fatigue, muscle and/or joint pain, genital dryness), and applies a recall period of 24 hrs. The aim of the SSSD is to establish patient reported endpoints for the treatment of Sjogrens syndrome. Participants will complete the diary daily for 7 days prior to the scheduled dosing.

    Time frame: 48 weeks

  2. Percentage of participants achieving ESSDAI response at Week 48**

    Efficacy (Plan A and B) Dose response measured by change multi-dimensional disease activity as assessed by the physician. Score range is 0-123. Higher scores on the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states A negative change from baseline indicates improvement in disease status

    Time frame: 48 weeks

  3. Percentage of participants achieving ESSDAI score <5 at Week 48

    Efficacy (Plan A and B) Dose response measured by change multi-dimensional disease activity as assessed by the physician. Score range is 0-123. Higher scores on the EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) scale are associated with poorer health states A negative change from baseline indicates improvement in disease status

    Time frame: 48 weeks

  4. Percentage of participants achieving SSSD response at Week 48**

    Efficacy (Plan A and B) The Sjogrens Syndrome Symptom Diary (SSSD) is questionnaire consists of five (six for females) questions about symptoms of Sjögren's syndrome, each question given a score of 0-10 (0=no symptoms, 10=worst possible symptoms) where patient choose the one response that best describes how severe the symptom was at its worst in the PAST 24 HOURS. It includes six symptom items (eye dryness, mouth dryness, skin dryness, physical fatigue, muscle and/or joint pain, genital dryness), and applies a recall period of 24 hrs. The aim of the SSSD is to establish patient reported endpoints for the treatment of Sjogrens syndrome. Participants will complete the diary daily for 7 days prior to the scheduled dosing.

    Time frame: 48 weeks

  5. Change from baseline in stimulated whole salivary flow rate at Week 48

    Efficacy (Plan A and B) Both the amount and composition of saliva has been shown to reflect the glandular damage caused by the disease process of Sjögren's (Pijpe et al 2007). Unstimulated and stimulated salivary secretions are collected over 5 minutes. As much as possible the assessments are to be performed at a fixed time of the day to minimize fluctuations related to the circadian rhythm of salivary flow and composition (Dawes 1972).

    Time frame: 48 weeks

  6. Change from baseline in PhGA at Week 48

    Efficacy (Plan A and B) Physician global assessment of disease activity is made with relation to Sjögren's syndrome. Physician's global assessment (PhGA) of disease activity for Sjögren's syndrome is performed using 3 separate scales: * Visual Analog Scale (VAS) - an unnumbered 100 mm long horizontal line ranging from "no disease activity' to "maximal disease activity". The assessment of patient's condition on the day is made by placing a vertical mark across the line. * Numerical Rating Scale (NRS) - a segmented numeric version of the VAS. A respondent needs to select a whole number (0-10 integers), with 0 being "no disease activity" and 10 being "maximal disease activity". * 4-point Likert scale - The level of disease activity is assessed on a scale from "inactive" to "high activity".

    Time frame: 48 weeks

  7. Change from baseline in PaGA at Week 48

    Efficacy (Plan A and B) Patient's global assessment (PaGA) of disease activity for Sjögren's syndrome is performed using 3 separate scales: * Visual Analog Scale (VAS) - an unnumbered 100 mm long horizontal line ranging from "very good' to "very poor". The assessment is made by placing a vertical mark across the line. * Numerical Rating Scale - a segmented numeric version of the VAS. A respondent needs to select a whole number (0-10 integers), with 0 being "very poor" and 10 being "very good". * 4-point Likert scale - The level of symptom severity is assessed on a scale from "none to severe".

    Time frame: 48 weeks

  8. Change from baseline in FACIT-F score at Week 48

    Efficacy (Plan A and B) The Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F version 4) is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week (Webster et al 2003). The level of fatigue is measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much).

    Time frame: 48 weeks

  9. Change from baseline in ESSPRI score at Week 48

    Efficacy (Plan B) ESSPRI is an established disease outcome measure for Sjögren's (Seror et al 2011, Seror et al 2015). It consists of three domains of dryness, pain and fatigue. The subject assesses severity of symptoms they experience on a single 0-10 numerical scale for each of the three domains. The ESSPRI score is defined as the mean of scores from the three scales: (dryness + pain + fatigue) /3. ESSPRI will be applied to the study patients at during runin period, at baseline and during study treatment.

    Time frame: 48 weeks

  10. Percentage of participants achieving ESSPRI response at Week 48**

    Efficacy (Plan B) ESSPRI is an established disease outcome measure for Sjögren's (Seror et al 2011, Seror et al 2015). It consists of three domains of dryness, pain and fatigue. The subject assesses severity of symptoms they experience on a single 0-10 numerical scale for each of the three domains. The ESSPRI score is defined as the mean of scores from the three scales: (dryness + pain + fatigue) /3. ESSPRI will be applied to the study patients at during run-in period, at baseline and during study treatment.

    Time frame: 48 Weeks

Other outcomes

  1. Incidence of Treatment-emergent AEs (TEAEs) /SAEs (Serious Adverse Event) upto the end of the study

    Safety(Plan A and B)

    Time frame: Through study completion up to two years

  2. Incidence of anti-ianalumab antibodies in serum Anti Drug Antibody (ADA) assay to end of study

    Immunogenicity (Plan A and B)

    Time frame: through study completion up to 2 years

  3. Ianalumab concentration in serum during the treatment and follow-up (up to the end of study)

    Pharmacokinetics (Plan A and B)

    Time frame: throughout study completion up to 2 years

07

Study locations

146 sites
  • Providence Medical Foundation
    Fullerton, California 92835, United States
  • Advanced Medical Research
    La Palma, California 90623, United States
  • Bay Area Arthritis And Osteoporosis
    Brandon, Florida 33511, United States
  • GNP Research
    Cooper City, Florida 33024, United States
  • Sarasota Arthritis Res Ctr
    Sarasota, Florida 34239, United States
  • Augusta University Georgia
    Augusta, Georgia 30912, United States
  • North Georgia Rheumatology Group
    Lawrenceville, Georgia 30046, United States
  • Clin Invest Specialists Inc
    Orland Park, Illinois 60467, United States
  • Clinic of Robert Hozman
    Skokie, Illinois 60176, United States
  • Clinical Investigation Specialists, Inc.
    Wauconda, Illinois 60084, United States
  • University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • Tufts School of Dental Medicine
    Boston, Massachusetts 02111, United States
  • Arthritis Osteoporosis Assoc of NM
    Las Cruces, New Mexico 88011, United States
  • St Lawrence Health System
    Potsdam, New York 13676, United States
  • Arthritis and Osteoporosis
    Charlotte, North Carolina 28202, United States
  • On Site Clinical Solutions Llc
    Charlotte, North Carolina 28202, United States
  • RAO Research LLC
    Oklahoma City, Oklahoma 73116, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Ramesh C Gupta MD Memphis TN
    Memphis, Tennessee 38119, United States
  • Prolato Clinical Research Center
    Houston, Texas 77054, United States
  • First Outpatient Research Unit
    San Antonio, Texas 78229, United States
  • Advanced Rheumatology of Houston
    Spring, Texas 77382, United States
  • Arthritis Northwest PLLC
    Spokane, Washington 99216, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1405BCH, Argentina
  • Novartis Investigative Site
    Quilmes, Buenos Aires 1878, Argentina
  • Novartis Investigative Site
    San Miguel Tucuman, Tucumán Province T4000DPK, Argentina
  • Novartis Investigative Site
    Buenos Aires, 1646, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1055AAF, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1428DQG, Argentina
  • Novartis Investigative Site
    Maroochydore, Queensland 4558, Australia
  • Novartis Investigative Site
    Woodville South, South Australia 5011, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40150 150, Brazil
  • Novartis Investigative Site
    Curitiba, Paraná 80030-110, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04266 010, Brazil
  • Novartis Investigative Site
    Burgas, 8000, Bulgaria
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site
    Sofia, 1606, Bulgaria
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1L7, Canada
  • Novartis Investigative Site
    Sydney, Nova Scotia B1P 1P3, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5T 2S8, Canada
  • Novartis Investigative Site
    Rimouski, Quebec G5L 5T1, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1G 2E8, Canada
  • Novartis Investigative Site
    Trois-Rivières, Quebec G9A 3Y2, Canada
  • Novartis Investigative Site
    Concepción, Biobio 4070280, Chile
  • Novartis Investigative Site
    Valdivia, Los Ríos Region 5110683, Chile
  • Novartis Investigative Site
    Santiago, RM 7500588, Chile
  • Novartis Investigative Site
    Hefei, Anhui 230001, China
  • Novartis Investigative Site
    Chongqing, Chongqing Municipality 400010, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210008, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Pingxiang, Jiangxi 337000, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030001, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Yinchuan, The Ningxia Hui Autonomous Reg 750000, China
  • Novartis Investigative Site
    Ürümqi, Xinjiang 830001, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310006, China
  • Novartis Investigative Site
    Beijing, 100029, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Shanghai, 200011, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Xinxiang, 453099, China
  • Novartis Investigative Site
    Medellín, Antioquia 050001, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlántico 080002, Colombia
  • Novartis Investigative Site
    Bogota, Cundinamarca 110221, Colombia
  • Novartis Investigative Site
    Bucaramanga, Santander Department 680003, Colombia
  • Novartis Investigative Site
    Angers, 49933, France
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Le Kremlin-Bicêtre, 94275, France
  • Novartis Investigative Site
    Le Mans, 72000, France
  • Novartis Investigative Site
    Strasbourg, 67000, France
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Hanover, 30625, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Athens, 115 21, Greece
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Székesfehérvár, Fejér 8000, Hungary
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Eger, 3300, Hungary
  • Novartis Investigative Site
    Gyula, 5700, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380013, India
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380015, India
  • Novartis Investigative Site
    Bangalore, Karnataka 560 002, India
  • Novartis Investigative Site
    Pune, Maharashtra 411001, India
  • Novartis Investigative Site
    New Delhi, 110029, India
  • Novartis Investigative Site
    Kfar Saba, 4428164, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Milan, MI 20100, Italy
  • Novartis Investigative Site
    Salerno, SA 84131, Italy
  • Novartis Investigative Site
    Udine, UD 33100, Italy
  • Novartis Investigative Site
    Naples, 80131, Italy
  • Novartis Investigative Site
    Nagoya, Aichi-ken 455-8530, Japan
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4578510, Japan
  • Novartis Investigative Site
    Nagoya, Aichi-ken 4578511, Japan

Showing the first 100 of 146 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in May 2025, 33 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2022
First posted
Apr 27, 2022
StartActual
Aug 4, 2022
Primary completionActual
May 13, 2025
CompletionEst.
Apr 15, 2027
Results delay requested
May 8, 2026
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05349214
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Aug 4, 2022
Primary completion
May 13, 2025
Completion
Apr 15, 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion